(4-(1-MORPHOLINOCYCLOPROPYL)PHENYL)BORONIC ACID PINACOL ESTER, 95.0%, 1g

Benzyl 3-hydroxybenzoate, 98%, 1g

Methyl 2-hydroxy-6-nitrobenzoate, 95.0%, 1g

2,6-Dichloropyridine-4-carboxylic acid, 97.0%, 25g

4-(Furan-2-ylmethyl)thiomorpholine 1,1-dioxide, 98%, 250mg

5-Iodopent-1-yne, 97%, 1g

2-Phenylbenzo[d]oxazole-6-carboxylic acid, 97%, 5g

Oxion Inverso OX.2053-PLPH-ICSI avec objectifs LWD Plan phase 10x/20x/40x, équipement ICSI et table croisée XY

3-Bromo-o-xylene, 98.0%, 25g

6-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)-N-(4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzyl)hexanamide, 95%, 100mg

(4-Methyl-3-nitrophenyl)boronic acid, 95.0%, 25g

1-Hydroxy-6-(methylsulfonyl)indole, 95.0%, 10g

METHYL 2-OXO-2-(THIOPHEN-3-YL)ACETATE, 95.0%, 100mg